Cargando…

Phosphorylation of different tau sites during progression of Alzheimer’s disease

Alzheimer’s disease is characterized by accumulation of amyloid plaques and tau aggregates in several cortical brain regions. Tau phosphorylation causes formation of neurofibrillary tangles and neuropil threads. Phosphorylation at tau Ser202/Thr205 is well characterized since labeling of this site i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neddens, Joerg, Temmel, Magdalena, Flunkert, Stefanie, Kerschbaumer, Bianca, Hoeller, Christina, Loeffler, Tina, Niederkofler, Vera, Daum, Guenther, Attems, Johannes, Hutter-Paier, Birgit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027763/ https://www.ncbi.nlm.nih.gov/pubmed/29958544 http://dx.doi.org/10.1186/s40478-018-0557-6

Ejemplares similares

Constant Levels of Tau Phosphorylation in the Brain of htau Mice
por: Neddens, Joerg, et al.
Publicado: (2020)

Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer’s disease and related murine models
por: Neddens, Joerg, et al.
Publicado: (2020)

mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms
por: Scherz, Barbara, et al.
Publicado: (2018)

Metabolic, Phenotypic, and Neuropathological Characterization of the Tg4-42 Mouse Model for Alzheimer’s Disease
por: Hinteregger, Barbara, et al.
Publicado: (2021)

Hepatic and neuronal phenotype of NPC1(−/−) mice
por: Santiago-Mujica, Estibaliz, et al.
Publicado: (2019)

Decreased Plasma Aβ in Hyperlipidemic APP(SL) Transgenic Mice Is Associated with BBB Dysfunction
por: Löffler, Tina, et al.
Publicado: (2016)

Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling
por: Filip, Thomas, et al.
Publicado: (2021)

Transgene integration causes RARB downregulation in homozygous Tg4–42 mice
por: Hinteregger, Barbara, et al.
Publicado: (2020)

Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value
por: Loeffler, Tina, et al.
Publicado: (2020)

Evaluation of Neuropathological Features in the SOD1-G93A Low Copy Number Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
por: Molnar-Kasza, Agnes, et al.
Publicado: (2021)

Quantification of Huntington’s Disease Related Markers in the R6/2 Mouse Model
por: Etxeberria-Rekalde, Estibaliz, et al.
Publicado: (2021)

Stable Mutated tau441 Transfected SH-SY5Y Cells as Screening Tool for Alzheimer’s Disease Drug Candidates
por: Löffler, Tina, et al.
Publicado: (2012)

Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease
por: Schiffer, Victoria, et al.
Publicado: (2020)

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
por: Rabl, R., et al.
Publicado: (2017)

Neuroinflammation and related neuropathologies in APP(SL) mice: further value of this in vivo model of Alzheimer’s disease
por: Löffler, Tina, et al.
Publicado: (2014)

Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model
por: Amschl, David, et al.
Publicado: (2013)

Editorial: Neuronopathic lysosomal storage diseases - specific neuronal characteristics and therapeutic approaches
por: Flunkert, Stefanie, et al.
Publicado: (2022)

Non-Selective Calcium Channel Blocker Bepridil Decreases Secondary Pathology in Mice after Photothrombotic Cortical Lesion
por: Lipsanen, Anu, et al.
Publicado: (2013)

Leukotriene Signaling as a Target in α-Synucleinopathies
por: Strempfl, Katharina, et al.
Publicado: (2022)

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease
por: Kutzsche, Janine, et al.
Publicado: (2017)

Evaluating the effect of R-Baclofen and LP-211 on autistic behavior of the BTBR and Fmr1-KO mouse models
por: Sharghi, Shirin, et al.
Publicado: (2023)

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study
por: Klaver, Andrea C., et al.
Publicado: (2017)

Epigenetic Modulation on Tau Phosphorylation in Alzheimer's Disease
por: Yu, Chao-Chao, et al.
Publicado: (2019)

Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
por: Rawat, Priyanka, et al.
Publicado: (2022)

Development of GMP‐1 a molecular chaperone network modulator protecting mitochondrial function and its assessment in fly and mice models of Alzheimer's disease
por: Pavlov, Pavel F., et al.
Publicado: (2018)

Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease
por: Zhou, Yan, et al.
Publicado: (2018)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer’s disease
por: Lau, Dawn H. W., et al.
Publicado: (2016)

PKR kinase directly regulates tau expression and Alzheimer's disease‐related tau phosphorylation
por: Reimer, Lasse, et al.
Publicado: (2020)

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease
por: Lai, Robert Y. K., et al.
Publicado: (2016)

Estimation of Tau and Phosphorylated Tau(181) in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
por: Shekhar, Shashank, et al.
Publicado: (2016)

Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease
por: Koppel, Jeremy, et al.
Publicado: (2016)

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
por: den Haan, Jurre, et al.
Publicado: (2018)

Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer’s disease?
por: Saura, Carlos A, et al.
Publicado: (2023)

Effect of pesticides on phosphorylation of tau protein, and its influence on Alzheimer’s disease
por: Torres-Sánchez, Erandis D, et al.
Publicado: (2023)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse model
por: Daschil, Nina, et al.
Publicado: (2015)

CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer’s disease as an indicator of tau phosphorylation
por: Shim, Kyu Hwan, et al.
Publicado: (2020)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tjqjo5m1hndget0bviak536c9l